← Browse by Condition
Medical Condition

smarcb1 deficient malignancies

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06444880 Phase 2
Recruiting

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Enrollment
40 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →